¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾ Á¦Á¦ ½ÃÀå º¸°í¼­ : ¾àǰ Á¾·ùº°, Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)
Erythropoietin Drugs Market Report by Drug Class, Product Type, Application, End-User, and Region 2024-2032
»óǰÄÚµå : 1541332
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 140 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,130,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,507,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 6,884,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾ Á¦Á¦ ½ÃÀå ±Ô¸ð´Â 2023³â 110¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀåÀÌ 2024-2032³â »çÀÌ 5%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇϸç 173¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ºóÇ÷°ú ¾ÏÀÇ À¯º´·ü Áõ°¡, ¸¸¼º ½ÅÀå Áúȯ Ä¡·á¿¡ ´ëÇÑ Àû¿ë Áõ°¡, ¾à¹°ÀÇ ÀáÀçÀû È¿°ú¿¡ ´ëÇÑ ´ëÁßÀÇ ÀÎ½Ä Áõ°¡°¡ ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.

¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾(EPO) Á¦Á¦´Â ¿¡Æ÷¿¡Æ¾ ¾ËÆÄ, ¿¡Æ÷¿¡Æ¾ º£Å¸, ´Þº£Æ÷¿¡Æ¾ ¾ËÆÄ µî ´Ù¾çÇÑ ¾à¹°·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç, ü³» EPO °áÇÌÀ» Ä¡·áÇϱâ À§ÇØ ¼ÒºñµË´Ï´Ù. À̵éÀº ÀçÁ¶ÇÕ µ¥¿Á½Ã¸®º¸ÇÙ»ê(DNA) ±â¼úÀ» ÀÌ¿ëÇÏ¿© ÇÕ¼ºÀûÀ¸·Î Á¦Á¶µË´Ï´Ù. °ñ¼ö¿¡¼­ ÀûÇ÷±¸(RBC) »ý¼ºÀ» ÀÚ±ØÇÏ¿© ü³» Çì¸ð±Û·Îºó ³óµµ¸¦ Á¶ÀýÇÕ´Ï´Ù. ü³» ÀûÇ÷±¸ÀÇ ¾çÀ» °Ç°­ÇÏ°Ô À¯ÁöÇϸ鼭 Áö±¸·Â °­È­, ÇǷΰ¨ °¨¼Ò, ½ÅÁø´ë»ç °³¼±, ±ÙÀ° Ä¡À¯ °úÁ¤ °³¼±¿¡ µµ¿òÀ» ÁÝ´Ï´Ù. ºóÇ÷, ¸»±â ½ÅºÎÀü, ÀÎü¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV), Ç÷¾×ÇÐ µî ´Ù¾çÇÑ Áúº´À» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ ¿Ü¿¡µµ EPO Á¦Á¦´Â ±ÙÀ°¿¡ »ê¼Ò °ø±Þ ´É·ÂÀ» Çâ»ó½ÃŰ´Â È¿°ú°¡ Àֱ⠶§¹®¿¡ ¿îµ¿ ¼±¼öÀÇ ¿îµ¿ ´É·Â°ú À¯»ê¼Ò ¿îµ¿ ´É·ÂÀ» Çâ»ó½Ã۱â À§ÇØ ¼ÒºñµË´Ï´Ù.

¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾ Á¦Á¦ ½ÃÀå µ¿Çâ

ÇöÀç ¾Ï°ú ½Å°æÁúȯ(ÀÚÆóÁõ, ³úÁ¾¾ç, ³ú¼º¸¶ºñ, °£Áú, ÁÖÀǷ°áÇÌÀå¾Ö(ADD) µî)ÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ EPO Á¦Á¦¿¡ ´ëÇÑ ´ëÁßÀÇ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¿©±â¿¡ EPO ¾à¹°°ú ±× È¿°ú¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü ¼¼°è ´ëÁßµé »çÀÌ¿¡¼­ ¿Ü°úÀû °³ÀÔ¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À̴ ȯÀÚÀÇ ¼ö¼ú ÈÄ µ¿Á¾ ¼öÇ÷À» ÁÙÀ̱â À§ÇØ EPO ¾à¹°ÀÇ »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î Àü ¼¼°è °³ÀÎÀÇ ¸¸¼º ½ÅÀå Áúȯ(CKD) ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¾÷°è ÅõÀÚÀÚ¿¡°Ô À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀûÇ÷±¸(RBC) Áõ°¡ ¹× ÇÇ·Î °¨¼Ò¿Í °°Àº EPO ¾à¹°ÀÌ Á¦°øÇÏ´Â ´Ù¾çÇÑ ÀÌÁ¡ÀÌ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, Àü ¼¼°èÀûÀ¸·Î ¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾ ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ ºü¸£°Ô »ó¿ëÈ­µÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â Àü ¼¼°èÀûÀ¸·Î ·¹ÆÛ·±½º ÀǾàǰº¸´Ù ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰ¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö´Â Ãß¼¼¿Í ÇÔ²² ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î Ä¡·áÁ¦·Î¼­ EPO Á¦Á¦°¡ ¿¬±¸ ±â°ü¿¡¼­ ¸¹Àº ¿¬±¸ ¸ñÀûÀ¸·Î Ȱ¿ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®µé

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾ Á¦Á¦ ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : ¾à¹° Á¾·ùº°

Á¦7Àå ½ÃÀå ³»¿ª : Á¦Ç° À¯Çüº°

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦11Àå SWOT ºÐ¼®

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global erythropoietin drugs market size reached US$ 11.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032. The growing prevalence of anemia and cancer, increasing application in treating chronic kidney disease, and rising awareness among the masses about the potential effects of the drug represent some of the key factors driving the market.

Erythropoietin (EPO) drugs comprise various drugs, such as epoetin-alfa, epoetin-beta, and darbepoetin-alfa, that are consumed to cure EPO deficiency in the body. They are manufactured synthetically using recombinant deoxyribonucleic acid (DNA) technology. They stimulate the production of red blood cells (RBCs) in bone marrow and regulate the concentration of hemoglobin in the body. They assist in enhancing endurance, reducing tiredness, increasing metabolism, and improving the healing process of muscles while maintaining a healthy amount of erythrocytes in the body. They are utilized to treat various diseases, such as anemia, end-stage renal disease, human immunodeficiency virus (HIV), and hematology, among individuals. Besides this, EPO drugs are consumed by athletes to enhance their performance and aerobic capacity, as they benefit in increasing the availability of oxygen to their muscles.

Erythropoietin Drugs Market Trends:

At present, the rising demand for EPO drugs among the masses due to the increasing prevalence of cancer and neurological diseases, such as autism, brain tumors, cerebral palsy, epilepsy, and attention deficit disorder (ADD), among individuals represents one of the key factors supporting the growth of the market. Besides this, the growing awareness among the masses about the EPO drugs and their effectiveness is offering a positive market outlook. Additionally, there is a rise in the need for surgical interventions among the masses around the world. This, coupled with the increasing utilization of EPO drugs to reduce allogeneic blood transfusions after surgical procedures in patients, is propelling the growth of the market. Apart from this, the rising number of chronic kidney disease (CKD) cases among individuals across the globe are offering lucrative growth opportunities to industry investors. Moreover, various benefits offered by EPO drugs, such as increasing red blood cells (RBCs) and reducing fatigue, are positively influencing the market. In addition to this, the rapid commercialization of erythropoietin biosimilars around the world is impelling the growth of the market. This, coupled with the increasing preference for biosimilar drugs rather than reference drugs across the globe, is contributing to the growth of the market. Furthermore, the rising utilization of EPO drugs as novel therapeutic agents in research institutes for numerous research purposes is strengthening the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global erythropoietin drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, product type, application and end user.

Drug Class Insights:

Biologics

Biosimilars

The report has provided a detailed breakup and analysis of the erythropoietin drugs market based on the drug class. This includes biologics and biosimilars. According to the report, biologics represented the largest segment.

Product Type Insights:

Epoetin-alfa

Epoetin-beta

Darbepoetin-alfa

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the product type has also been provided in the report. This includes epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. According to the report, epoetin-alfa accounted for the largest market share.

Application Insights:

Hematology

Kidney Disorder

Cancer

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the application has also been provided in the report. This includes hematology, kidney disorder, cancer, and others. According to the report, kidney disorder accounted for the largest market share.

End-User Insights:

Hospitals

Homecare

Specialty Clinics

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the end-user has also been provided in the report. This includes hospitals, homecare, specialty clinics, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for erythropoietin drugs. Some of the factors driving the North America erythropoietin drugs market included the increasing approvals of erythropoietin drugs, various incentives offered by governing agencies for research on chronic diseases, rising prevalence of cancer among individuals, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global erythropoietin drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., Biocon Limited, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Erythropoietin Drugs Market

6 Market Breakup by Drug Class

7 Market Breakup by Product Type

8 Market Breakup by Application

9 Market Breakup by End User

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â